In a recent article, eXoZymes (Nasdaq: EXOZ) was featured in The Village Voice for its work on NCT (N-trans-Caffeoyltyramine), a naturally occurring molecule at the center of a growing scientific conversation about metabolic health beyond GLP-1 weight-loss drugs.  
  
eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1.  
  
eXoZymes has developed cell-free biomanufacturing methods capable of producing high-purity NCT at scale, turning a molecule once found only in trace amounts in peppercorns (roughly 0.0014 percent concentration) into one that can now be explored in depth. The article places that capability in the context of a broader shift in metabolic health research, where scientists are looking past appetite suppression toward approaches that address how the body burns energy at the cellular level.  
  
With over 1.4 billion people worldwide affected by obesity, diabetes, and metabolic dysfunction, the interest is growing. Preclinical research published in Nature Cell Death & Disease showed a roughly 30 percent reduction in weight gain in mouse models on a high-fat diet receiving NCT, with no change in food intake. While further studies are required before conclusions about human health can be drawn, the Village Voice piece places eXoZymes squarely at the forefront of the ongoing effort to produce the NCT molecule at scale.  
  
Read the complete article: [https://www.villagevoice.com/the-metabolic-engine-how-scientists-are-exploring-a-new-path-beyond-glp-1-weight-loss-drugs/](https://www.villagevoice.com/the-metabolic-engine-how-scientists-are-exploring-a-new-path-beyond-glp-1-weight-loss-drugs/)  
  
eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel.  
  
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.  
  
Learn more about eXoZymes Inc. at https://exozymes.com. For investor inquiries, visit [https://exozymes.com/investor](https://exozymes.com/investor) and learn about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.  
  
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

In a recent article, eXoZymes (Nasdaq: EXOZ) was featured in The Village Voice for its work on NCT (N-trans-Caffeoyltyramine), a naturally occurring molecule at the center of a growing scientific conversation about metabolic health beyond GLP-1 weight-loss drugs.